Dr Leila Eshraghi

Role: Senior Research Officer
Lab/Group: Connie Johnson Breast Cancer Research Lab

Education

2013Doctor of Philosophy (Doctor of Philosophy (Ph.D)), Molecular BiologyMurdoch University, Australia

Selected publications

See all publications

2025
Journal of Experimental & Clinical Cancer Research : CR10.1186/s13046-025-03466-9
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.
Sarah Alexandrou, Christine S Lee, Kristine J Fernandez, Celine E Wiharja, Leila Eshraghi, John Reeves, Daniel A Reed, Neil Portman, Zoe Phan, Heloisa H Milioli, Iva Nikolic, Antonia L Cadell, David R Croucher, Kaylene J Simpson, Elgene Lim, Theresa E Hickey, Ewan K A Millar, Carla L Alves, Henrik J Ditzel, C Elizabeth Caldon
2024
Cellular and Molecular Life Sciences : CMLS10.1007/s00018-024-05183-6
PALB2-mutated human mammary cells display a broad spectrum of morphological and functional abnormalities induced by increased TGFβ signaling.
Hanna Tuppurainen, Niina Laurila, Marjut Nätynki, Leila Eshraghi, Anna Tervasmäki, Louisa Erichsen, Claus Storgaard Sørensen, Katri Pylkäs, Robert Winqvist, Hellevi Peltoketo
2021
Leukemia10.1038/s41375-021-01246-w
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
Deepak Singhal, Christopher N Hahn, Simone Feurstein, Li Yan A Wee, Luke Moma, Monika M Kutyna, Rakchha Chhetri, Leila Eshraghi, Andreas W Schreiber, Jinghua Feng, Paul P-S Wang, Milena Babic, Wendy T Parker, Song Gao, Sarah Moore, Soma Das, David Thomas, Swetansu Pattnaik, Anna L Brown, Richard J D'Andrea, Nicola K Poplawski, Daniel Thomas, Hamish S Scott, Lucy A Godley, Devendra K Hiwase

See all Garvan publications

Explore our research

Our impact

Our people

News and resources

About us

Support Us

Dr Leila Eshraghi

Education

Selected publications

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

PALB2-mutated human mammary cells display a broad spectrum of morphological and functional abnormalities induced by increased TGFβ signaling.

Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.